JP2024506904A - 治療剤としてのｃＧＡＳ活性の阻害剤 - Google Patents

治療剤としてのｃＧＡＳ活性の阻害剤 Download PDF

Info

Publication number
JP2024506904A
JP2024506904A JP2023548654A JP2023548654A JP2024506904A JP 2024506904 A JP2024506904 A JP 2024506904A JP 2023548654 A JP2023548654 A JP 2023548654A JP 2023548654 A JP2023548654 A JP 2023548654A JP 2024506904 A JP2024506904 A JP 2024506904A
Authority
JP
Japan
Prior art keywords
methylbenzofuro
alkyl
pyrrolidine
carboxylic acid
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506904A5 (https=
Inventor
ジー． ローリー，ロバート
クマール，ミーラー
ボクサー，マシュー
マロニー，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of JP2024506904A publication Critical patent/JP2024506904A/ja
Publication of JP2024506904A5 publication Critical patent/JP2024506904A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023548654A 2021-02-11 2022-02-11 治療剤としてのｃＧＡＳ活性の阻害剤 Pending JP2024506904A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148201P 2021-02-11 2021-02-11
US63/148,201 2021-02-11
PCT/US2022/016073 WO2022174012A1 (en) 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Publications (2)

Publication Number Publication Date
JP2024506904A true JP2024506904A (ja) 2024-02-15
JP2024506904A5 JP2024506904A5 (https=) 2025-02-19

Family

ID=82837325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548654A Pending JP2024506904A (ja) 2021-02-11 2022-02-11 治療剤としてのｃＧＡＳ活性の阻害剤

Country Status (8)

Country Link
US (1) US20240174684A1 (https=)
EP (1) EP4291188A4 (https=)
JP (1) JP2024506904A (https=)
KR (1) KR20230144550A (https=)
CN (1) CN116997339A (https=)
AU (1) AU2022218787A1 (https=)
CA (1) CA3206520A1 (https=)
WO (1) WO2022174012A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) * 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
JP2009543775A (ja) * 2006-07-11 2009-12-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2020142729A1 (en) * 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543775A (ja) * 2006-07-11 2009-12-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2020142729A1 (en) * 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents

Also Published As

Publication number Publication date
WO2022174012A1 (en) 2022-08-18
KR20230144550A (ko) 2023-10-16
EP4291188A1 (en) 2023-12-20
US20240174684A1 (en) 2024-05-30
AU2022218787A1 (en) 2023-08-17
EP4291188A4 (en) 2025-01-08
CA3206520A1 (en) 2022-08-18
CN116997339A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
JP2024506904A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
JP7443495B2 (ja) ヘテロ環式ｒｉｐ１キナーゼ阻害剤
US11820775B2 (en) Pyrrolopyrimidine ITK inhibitors
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107922431B (zh) Hpk1抑制剂及其使用方法
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
AU2005212409C1 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
CA3159561A1 (en) Ras inhibitors
JP7507161B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
KR20210025061A (ko) 세레블론(crbn)에 대한 리간드
WO2018222918A1 (en) Ire1 small molecule inhibitors
US20120077814A1 (en) Sulfonamide, sulfamate, and sulfamothioate derivatives
RS65319B1 (sr) 8-cijano-5-piperidino-hinolini kao tlr7/8 antagonisti i njihova upotreba u lečenju imunoloških poremećaja
AU2015225745A1 (en) Heterocyclic compounds
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
TW202322808A (zh) 治療疾病之化合物、組合物及方法
KR102288246B1 (ko) 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용
JP7551607B2 (ja) アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
JP2022519764A (ja) 二環式スルホンアミド
JP2022504082A (ja) ウイルス感染を処置するための２，６－ジメチル－Ｎ－（（ピリジン－４－イル）メチル）イミダゾ［１，２－ｂ］ピリダジン－８－アミンおよび２，５－ジメチル－Ｎ－［（ピリジン－４－イル）メチル］ピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体
JP2025528113A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
TW202432124A (zh) 蛋白質酪胺酸磷酸酶抑制劑、其組合物及使用方法
KR20240014050A (ko) Pd1/pd-l1 억제제로서의 화합물 및 이의 방법
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251120

A603 Late request for extension of time limit during examination

Free format text: JAPANESE INTERMEDIATE CODE: A603

Effective date: 20260330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420